Scientists at Washington University School of Medicine have identified a surprising immune pathway that may help drive Alzheimer's-related brain damage — and it starts outside the brain. A new study published in Nature Neuroscience found that T cells, which appear in unusually high numbers in the brains of Alzheimer's patients, are likely being activated in neck lymph nodes by dendritic cells before traveling into the nervous system and contributing to neurodegeneration.

When researchers eliminated these dendritic cells from the lymph nodes of mice prone to tau-related brain damage, the surge of harmful T cells in the brain largely disappeared — and so did the associated neurodegeneration. Crucially, tau tangles remained unchanged, yet the mice still preserved their cognitive abilities, suggesting that targeting this immune pathway could slow cognitive decline even without clearing the protein buildup itself.

Key Takeaways:

• T cell activation appears to occur in cervical lymph nodes, not the brain — making it a potentially more accessible therapeutic target
• Blocking dendritic cell activity reduced brain T cell infiltration and neurodegeneration without altering tau burden
• Many T cell-targeting therapies already exist and are approved for other diseases, offering a potential fast track for repurposing

Why it matters: One of the biggest hurdles in treating Alzheimer's is getting drugs past the blood-brain barrier. Since this newly identified pathway operates outside the brain, it could be targeted with existing immunotherapies — potentially bypassing that barrier entirely and accelerating the path to effective treatments.